The reason is simple: drug companies are prohibited from pro-actively sharing information about their products for uses beyond what the FDA has approved.
Dietary fat and simple-carbohydrate consumption be reduced in combination with drug therapy to lower the risk of pancreatitis for patients with severe and very severe hypertriglyceridemia.
The lesson here is clear and simple: It's perfectly possible for a biotech company to do well with a drug that might be small by the standards of the big drug firms.
But emerging new gene findings indicate that the high-priced drug may be useless in nearly half of colon cancer patients--and that a simple gene test could allow doctors to predict in advance which patients are likely to benefit.